Lintel MT Tablet ER contains a combination of Telmisartan 40 mg and Metoprolol Succinate 25 mg, formulated as an extended-release tablet for the management of hypertension and related cardiovascular conditions. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to a decrease in blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, further contributing to blood pressure control and reducing the risk of cardiovascular events. The extended-release formulation ensures a steady plasma concentration, enhancing patient compliance by allowing once-daily dosing. Lintel MT Tablet ER is indicated for the treatment of essential hypertension, providing improved blood pressure control through dual mechanisms. It may also be used in patients with concomitant ischemic heart disease or heart failure, under medical supervision. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy.